Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 20/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5872493 | 0.80 | CRHR1 (0.80) | CRHR1 | |
| SCHEMBL5872445 | 0.79 | CRHR1 (0.73) | CRHR1 | |
| SCHEMBL5872530 | 0.76 | CRHR1 (0.47) | CRHR1 | |
| SCHEMBL16606731 | 0.71 | CRHR1 (1.00) | CRHR1 | |
| SCHEMBL5599496 | 0.70 | CRHR1 (0.60) | CRHR1 | |
| SCHEMBL5599675 | 0.67 | CRHR1 (1.00) | CRHR1 | |
| SCHEMBL5599786 | 0.65 | CRHR1 (0.74) | CRHR1 | |
| SCHEMBL21227087 | 0.63 | CRHR1 (0.85) | CRHR1 | |
| SCHEMBL5600850 | 0.63 | CDK4 (0.51) | CRHR1 | |
| SCHEMBL5599550 | 0.60 | CRHR1 (1.00) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007522200-A | — | — | 2007-08-09 | — | — | JP | claimed |
| EP-1718311-A1 | THERAPEUTIC COMBINATIONS OF ATYPICAL ANTIPSYCHOTICS WITH CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2006-11-08 | — | — | EP | claimed |
| US-20050209250-A1 | Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists | PFIZER INC | 2005-09-22 | — | — | US | claimed |
| WO-2005079807-A1 | THERAPEUTIC COMBINATIONS OF ATYPICAL ANTIPSYCHOTICS WITH CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-09-01 | — | — | WO | claimed |
| US-20040082597-A1 | Use of CRF antagonists and related compositions | PFIZER INC | 2004-04-29 | — | — | US | claimed |
| US-20030199527-A1 | Use of corticotropin releasing factor antagonists and related compositions | HAMANAKA ERNEST S (US) | 2003-10-23 | — | — | US | claimed |
| US-20020156089-A1 | Use of CRF antagonists and related compositions | PFIZER INC. | 2002-10-24 | — | — | US | claimed |
| US-6432989-B1 | TREATING SLEEP DISORDERS | PFIZER INC | 2002-08-13 | — | — | US | claimed |
| US-20010041673-A1 | Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues | PFIZER INC. | 2001-11-15 | — | — | US | claimed |
| EP-1149583-A2 | Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues | Pfizer Products Inc. (US) | 2001-10-31 | — | — | EP | claimed |
| EP-1097709-A2 | Use of corticotropin releasing factor antagonists for treating syndrome X | Pfizer Products Inc. (US) | 2001-05-09 | — | — | EP | claimed |
| EP-1082960-A2 | Use of CRF antagonists and related compositions for treating depression and modifying the circadian rhytm | Pfizer Products Inc. (US) | 2001-03-14 | — | — | EP | claimed |
| US-20060270659-A1 | Pyrazolopyrimidines as CRF receptor antagonists | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-11-30 | — | — | US | disclosed |
| EP-1718311-A1 | THERAPEUTIC COMBINATIONS OF ATYPICAL ANTIPSYCHOTICS WITH CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2006-11-08 | — | — | EP | disclosed |
| EP-0880523-B1 | PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES INC (US) | 2006-08-16 | — | — | EP | disclosed |
| US-7074797-B2 | Pyrazolopyrimidines as CRF receptor antagonists | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-07-11 | — | — | US | disclosed |
| EP-1097709-A2 | Use of corticotropin releasing factor antagonists for treating syndrome X | Pfizer Products Inc. (US) | 2001-05-09 | — | — | EP | disclosed |
| EP-1082960-A2 | Use of CRF antagonists and related compositions for treating depression and modifying the circadian rhytm | Pfizer Products Inc. (US) | 2001-03-14 | — | — | EP | disclosed |
| EP-0880523-A1 | PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-12-02 | — | — | EP | disclosed |
| WO-1997029109-A1 | PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270659-A1 | Pyrazolopyrimidines as CRF receptor antagonists | HTR5A, OPRL1, CRHR1 | CRHR1 3/4885 |
| US-20050209250-A1 | Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists | CRH, MC2R, CRHR2 | CRHR1 5/4885 |
| US-20020156089-A1 | Use of CRF antagonists and related compositions | CRH, CRHR1, CRHR2 | CRHR1 2/4885 |
| US-20010041673-A1 | Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues | CRH, GHSR, GHRHR | CRHR1 4/4885 |
| US-20030199527-A1 | Use of corticotropin releasing factor antagonists and related compositions | CRH, CRHR1, CRHR2 | CRHR1 2/4885 |
| US-20040082597-A1 | Use of CRF antagonists and related compositions | CRH, CRHR1, CRHR2 | CRHR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.